Factors Affecting the Adherence to Disease-Modifying Therapy in Patients With Multiple Sclerosis

被引:4
|
作者
von Gaudecker, Jane R. [1 ]
机构
[1] Indiana Univ, Sch Nursing, Indianapolis, IN 46204 USA
关键词
coping; fatigue; medication adherence; multiple sclerosis; nursing; self-efficacy;
D O I
10.1097/JNN.0000000000000405
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Adherence to medication treatment in patients with multiple sclerosis (MS) is important to increase its effectiveness, reduce patient disability, prevent attacks, and increase the quality of life. Aim: This study investigated factors that influence adherence to disease-modifying therapy in patients with MS. Methods: This descriptive study was conducted with 198 patients with MS who met the inclusion criteria and agreed to participate between July 2016 and February 2017. Data were collected using an Individual Identification Form that included sociodemographic characteristics, the Multiple Sclerosis Treatment Adherence Questionnaire, the Fatigue Severity Scale, the Self-Efficacy Scale, and the Brief COPE. Results: We found that 59.6% of the patients were adherent to therapy. Patients were significantly more adherent to Avonex than other treatments, and memory problems was the most common reason for missing or forgetting medication in nonadherent patients. There was a significant difference between medication adherence and some sociodemographic characteristics and disease characteristics (P < .05). There was no significant difference between coping attitudes, fatigue, and self-efficacy level and medication adherence (P > .05). Conclusion: Patients' adherence to medication treatment was low and may be associated with social, physical, and cognitive measures.
引用
收藏
页码:302 / 302
页数:1
相关论文
共 50 条
  • [31] Fostering adherence to injectable disease-modifying therapies in multiple sclerosis
    Lugaresi, Alessandra
    Rottoli, Maria Rosa
    Patti, Francesco
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (09) : 1029 - 1042
  • [32] Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations
    Evans, Charity
    Marrie, Ruth Ann
    Zhu, Feng
    Leung, Stella
    Lu, Xinya
    Kingwell, Elaine
    Zhao, Yinshan
    Tremlett, Helen
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 (06) : 702 - 711
  • [33] Association of measures of medication adherence and severe relapses with multiple sclerosis disease-modifying therapy
    Dickson, M.
    Kozma, C.
    Okuda, D. T.
    Fincher, C.
    Meletiche, D.
    VALUE IN HEALTH, 2008, 11 (03) : A22 - A22
  • [34] Factors that influence adherence with disease-modifying therapy in MS
    Katherine Treadaway
    Gary Cutter
    Amber Salter
    Sharon Lynch
    James Simsarian
    John Corboy
    Douglas Jeffery
    Bruce Cohen
    Ken Mankowski
    Joseph Guarnaccia
    Lawrence Schaeffer
    Roy Kanter
    David Brandes
    Charles Kaufman
    David Duncan
    Ellen Marder
    Arthur Allen
    John Harney
    Joanna Cooper
    Douglas Woo
    Olaf Stüve
    Michael Racke
    Elliot M. Frohman
    Journal of Neurology, 2009, 256 : 568 - 576
  • [35] Factors that influence adherence with disease-modifying therapy in MS
    Treadaway, Katherine
    Cutter, Gary
    Salter, Amber
    Lynch, Sharon
    Simsarian, James
    Corboy, John
    Jeffery, Douglas
    Cohen, Bruce
    Mankowski, Ken
    Guarnaccia, Joseph
    Schaeffer, Lawrence
    Kanter, Roy
    Brandes, David
    Kaufman, Charles
    Duncan, David
    Marder, Ellen
    Allen, Arthur
    Harney, John
    Cooper, Joanna
    Woo, Douglas
    Stuve, Olaf
    Racke, Michael
    Frohman, Elliot M.
    JOURNAL OF NEUROLOGY, 2009, 256 (04) : 568 - 576
  • [36] An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis
    Vaughn, Caila
    Bushra, Aisha
    Kolb, Channa
    Weinstock-Guttman, Bianca
    CNS DRUGS, 2018, 32 (02) : 161 - 178
  • [37] Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
    F. Schweitzer
    S. Laurent
    G. R. Fink
    Michael H. Barnett
    H. P. Hartung
    C. Warnke
    Journal of Neurology, 2021, 268 : 2379 - 2389
  • [38] Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis
    Sorensen, Per Soelberg
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2011, 311 : S29 - S34
  • [39] An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis
    Caila Vaughn
    Aisha Bushra
    Channa Kolb
    Bianca Weinstock-Guttman
    CNS Drugs, 2018, 32 : 161 - 178
  • [40] Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
    Schweitzer, F.
    Laurent, S.
    Fink, G. R.
    Barnett, Michael H.
    Hartung, H. P.
    Warnke, C.
    JOURNAL OF NEUROLOGY, 2021, 268 (07) : 2379 - 2389